ENDPOINTS

Prothena’s amyloidosis drug flops again, spending and s...

Prothena last week said it has abandoned its lead product after a Phase 3 amyloi...

Syndeio debuts with $90M+ to bring together synapse rep...

An Indianapolis-headquartered biotech reentered the neuroscience scene with more...

Exclusive: ProteinQure raises $11M Series A for peptide...

When Lucas Siow and his three fellow co-founders started ProteinQure in 2017, th...

Investors pump $130M into protein degrader startup Glyc...

Protein degrader shop GlycoEra, spun out of vaccines company LimmaTech in 2021, ...

TCG's R&D venture team makes a T cell engager deal with...

The Column Group's drug R&D team, known as TCG Labs Soleil, has been busy churni...

Analyzing the Endpoints 100; ‘Most favored nation’ targ...

Welcome back to another edition of Endpoints Weekly. We had another busy week ch...

Trump unofficially taps CMS chief Oz to spearhead 'most...

President Donald Trump unofficially asked CMS Administrator Mehmet Oz to lead th...

About 5% of CBER and CDER left after FDA staff cuts, an...

Nearly one out of every 20 staff in the FDA offices that oversee drugs and biolo...

US warns drugmakers against misrepresenting cost of imp...

The US Customs and Border Protection warned drugmakers against trying to evade i...

GLP-1s may cut cancer risk; Gyre’s stock falls after he...

Plus, news about Sanofi, Servier, BioNova, Arcutis, Roche, Satellos Bioscience, ...

CHMP clears path for GSK’s Blenrep relaunch, recommends...

GSK, Roche and SpringWorks Therapeutics were among those that secured a positive...

#ASCO25: Kura spells out pivotal AML trial win as it ge...

Kura Oncology said one-quarter of patients with certain forms of advanced acute ...

GLP-1s may cut cancer risk; Gyre’s stock falls after he...

Plus, news about Sanofi, Servier, BioNova, Arcutis, Roche, Satellos Bioscience, ...

Federal judge blocks RFK Jr. from reorganizing HHS

The Trump administration has been barred from carrying out its sweeping plan to ...

Gilead notches another Phase 3 win for Trodelvy in trip...

Gilead’s Trodelvy has passed another late-stage test in certain patients with me...

Geoffrey Porges exits Schrödinger with CFO swap; A new ...

Geoffrey Porges, a longtime biotech analyst and well-known Wall Street figure, s...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.